<a href="https://laohu8.com/S/MBRX">Moleculin Biotech</a> Secures RAMPA Approval to Expand Phase 3 MIRACLE Clinical Trial into Georgia, Boosting Global Enrollment Efforts
Moleculin Biotech Inc., a late-stage pharmaceutical company specializing in treatments for challenging cancers and viral infections, has received regulatory approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for its Phase 2B/3 MIRACLE clinical trial. This pivotal trial, which investigates the combination of Annamycin and cytarabine for treating refractory or relapsed acute myeloid leukemia $(AML.AU)$ in adults, is set to expand globally with sites in the US, Europe, and the Middle East. Following recent approval from the European Medicines Agency $(EMA)$, Moleculin plans to enhance its enrollment efforts by adding 16 additional clinical sites in Europe and the US by the end of August, aiming for over 30 sites for Part A of the trial. The company anticipates reporting initial data from Part A in the second half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-022386), on July 09, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。